Video

What the impact of 44-week aflibercept data may mean in a real-world setting

Author(s):

Sheryl Stevenson,Emily Kaiser Maharjan
Conferences|ASRS Preview

David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
CIME 2025: Neda Shamie, MD, on expanding options in pharmacological presbyopia management
Related Content
Ashvattha reports positive phase 2 data for migaldendranib in retinal diseases
May 19th 2025

Ashvattha reports positive phase 2 data for migaldendranib in retinal diseases

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Photo courtesy of Malvina Eydelman, MD)
May 18th 2025

Q&A: Malvina Eydelman, MD, on leading CCOI and catalyzing global ophthalmic innovation

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Q&A: Rishi Singh, MD, discusses real-world outcomes of patients with DME treated with faricimab
May 17th 2025

Q&A: Rishi Singh, MD, discusses real-world outcomes of patients with DME treated with faricimab

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies
May 16th 2025

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies

© 2025 MJH Life Sciences

All rights reserved.